NewAmsterdam Pharma Co N.V.
NAMSDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
3 upcoming, 2 past
How NAMS's past catalysts played out
Monotherapy obicetrapib
Dyslipidemias
Obicetrapib
Dyslipidemias
Obicetrapib 10 mg
Lipidemia
Obicetrapib 5mg
Dyslipidemias
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Dyslipidemias
Obicetrapib 10mg
Antioxidant Absorption
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Monotherapy obicetrapib | Phase 3 | Dyslipidemias | - | - |
Obicetrapib | Phase 3 | Dyslipidemias | - | - |
Obicetrapib 10 mg | Phase 3 | Lipidemia | - | - |
Obicetrapib 5mg | Phase 2 | Dyslipidemias | - | - |
obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks | Phase 2 | Dyslipidemias | - | - |
Obicetrapib 10mg | Phase 2 | Antioxidant Absorption | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in NewAmsterdam Pharma Co N.V.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in NewAmsterdam Pharma Co N.V.'s (NAMS) pipeline across Phase 3, Phase 2. Its lead program is Monotherapy obicetrapib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NewAmsterdam Pharma Co N.V.'s next FDA catalyst?→
NewAmsterdam Pharma Co N.V.'s (NAMS) next tracked catalyst is a Phase 2 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NAMS biotech catalysts?→
Add NAMS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NewAmsterdam Pharma Co N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.